One of the main goals of Life4me+ — is to prevent new cases of HIV and other STIs, hepatitis C and tuberculosis.

The app helps to establish anonym communication between physicians and HIV-positive people. It allows you to conveniently organize your medication intake timetable and set concealed and personalized reminders.

HIV-vaccine HVTN 705 trial will start this autumn

27 July 2017 10:07

At the The 9th International AIDS Society Conference  in Paris was announced that HIV-vaccine HVTN 705 trial will start this autumn. More than 2 500 south african women will participate in the research. Scientists explained that women will be given  HIV vaccine or a placebo and then followed for three years to see if it stops them becoming infected with HIV.

Janssen, the pharmaceutical company of the giant drug and health company Johnson and Johnson is the developer of the vaccine HVTN 705 and the initiators of the study.

Janssen’s Hanneke Schuitemaker told the conference that the vaccine for the new trial had been developed by Janssen during three separate trials, during which different components and combinations were trialled and the best picked.

“I feel we have reached a pivotal moment in HIV vaccine development,” - said Glenda Gray, scientist , she provided an overview at the symposium

Latest News

The Berlin patient rallies public to support HIV research funding

Timothy Ray Brown remains optimistic that the scientific and medical communities can and will achieve this if properly funded.

19 January 14:55

Fresh approach to tuberculosis vaccine offers better protection

Researchers use a weakened form of cytomegalovirus, or CMV, which infects most people without causing disease. They wove tiny bits of a disease-causing pathogen into the CMV. This re-engineered CMV creates and maintains a high state of immunity against the pathogen in vaccinated ...

19 January 08:46

Researchers Consider Hepatitis C Vertical Transmission Rates

The primary source of HCV infection in children is vertical, or mother-to-child, transmission, which occurs in 5% to 10% of at-risk pregnancies. The majority of at-risk pregnant women with chronic HCV acquired the disease through drug use.

18 January 16:07

New multipurpose device to help prevent HIV and pregnancy

RTI-lead team will develop an implant providing long-acting contraception and HIV prevention--the Subcutaneous Contraceptive and HIV Implant Engineered for Long-Acting Delivery (SCHIELD) device. SCHIELD will offer dual protection and be discrete, simple to administer and ...

18 January 14:40